Navigation Links
Tengion Appoints Jeff Randall to Board of Directors
Date:2/27/2008

EAST NORRITON, Pa., Feb. 27 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-vessels, announced today that it has appointed Jeff Randall to its Board of Directors. Mr. Randall brings more than 25 years experience as a senior- level executive, CFO and CEO at public and private companies to Tengion, including expertise in the healthcare, device manufacturing and electronics industries.

"We are pleased to welcome Jeff to the Tengion Board of Directors," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "His expertise in developing the financial infrastructure for biotech companies will be a valuable addition to our Board and we look forward to working with him."

Mr. Randall's career has included serving as CFO at seven companies, three of which then appointed him to the post of CEO. Now a financial consultant, he most previously held management team positions at Eximias Pharmaceutical Corporation and i-STAT Corporation and has extensive experience working with and serving on Boards of Directors. Mr. Randall received his B.S. from The Pennsylvania State University, his M.B.A. from Northeastern University and served in the U.S. Air Force.

"Tengion's technology and the strength of its management team and Board of Directors made this an exciting opportunity," said Mr. Randall. "I am looking forward to working with the company and my fellow members of the Board to realize Tengion's potential and help the company achieve its corporate goals."

About Tengion

Tengion, a clinical stage biotechnology company, has pioneered the Autologous Organ Regeneration Platform(TM) that catalyzes the body's innate ability to regenerate. Tengion's neo-organs and neo-tissues in development, such as bladders and vessels, combine biocompatible materials and a patient's own (autologous) cells to regenerate diseased and failing organs and tissues. Tengion's product candidates have the potential to cure - rather than treat - organ and tissue failure, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
2. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
4. Codexis Appoints Singapore Laboratories Managing Director
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. NeurogesX Appoints New Director to the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... President for Public Policy for the National Organization for Rare Disorders (NORD). Dorman ... to ensure their voices are heard throughout the drug regulatory review process. , ...
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/9/2016)... LEXINGTON, Massachusetts , February 9, 2016 ... Enables Children to Take Part in Life-Changing Camp ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> SHPG ) is announcing a ... with rare diseases, as well as the future of rare disease ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Insights, 2016", report provides in depth insights ... activities around the Protein-Tyrosine Phosphatase 1B (PTP1B) ... profiles in various stages of development including ... Phase III and Preregistration. Report covers the ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/20/2016)... , Jan. 20, 2016 A market ... to directly benefit from the explosion in genomics knowledge. ... Howe Sound Research. A range of dynamic trends are ... - personalized medicine - pharmacogenomics - pathogen evolution ... with large markets - greater understanding of the role ...
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
Breaking Biology News(10 mins):